A selective angiotensin receptor antagonist , Valsartan , produced regression of <font color="red">left_1</font> <font color="red">ventricular_1</font> <font color="red">hypertrophy_1</font> associated with a reduction of arterial stiffness . 
<br>
<br> We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a regressive effect on <font color="red">left_1</font> <font color="red">ventricular_1</font> <font color="red">hypertrophy_1</font> <font color="red">(_1</font> <font color="red">LVH_1</font> <font color="red">)_1</font> in patients on continuous ambulatory peritoneal dialysis ( CAPD ) . In a double - blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g / m2 for women and LVMi > 137 g / m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) . The target <font color="red">blood_1</font> <font color="red">pressure_1</font> <font color="red">(_1</font> <font color="red">BP_1</font> <font color="red">)_1</font> was 140/90 mmHg or lower in both groups . The following parameters were measured before and at the end of the study : <font color="red">aortic_1</font> <font color="red">and_1</font> <font color="red">large_1</font> <font color="red">-_1</font> <font color="red">artery_1</font> <font color="red">compliance_1</font> and <font color="red">arterial_1</font> <font color="red">wave_1</font> <font color="red">reflections_1</font> <font color="red">[_1</font> <font color="red">pulse_1</font> <font color="red">wave_1</font> <font color="red">velocity_1</font> <font color="red">(_1</font> <font color="red">PWV_1</font> <font color="red">)_1</font> <font color="red">and_1</font> <font color="red">augmentation_1</font> <font color="red">index_1</font> <font color="red">(_1</font> <font color="red">AI_1</font> <font color="red">)_1</font> <font color="red">application_1</font> <font color="red">tonometry_1</font> <font color="red">]_1</font> and <font color="red">cardiac_1</font> <font color="red">echocardiography_1</font> <font color="red">._1</font> Periodically recorded were <font color="red">body_1</font> <font color="red">weight_1</font> <font color="red">,_1</font> <font color="red">BP_1</font> <font color="red">(_1</font> <font color="red">mercury_1</font> <font color="red">sphygmomanometer_1</font> <font color="red">)_1</font> <font color="red">,_1</font> <font color="red">serum_1</font> <font color="red">creatinine_1</font> <font color="red">,_1</font> <font color="red">electrolytes_1</font> <font color="red">,_1</font> <font color="red">complete_1</font> <font color="red">blood_1</font> <font color="red">cell_1</font> <font color="red">counts_1</font> <font color="red">,_1</font> <font color="red">urine_1</font> <font color="red">volume_1</font> <font color="red">,_1</font> <font color="red">drainage_1</font> <font color="red">volume_1</font> <font color="red">,_1</font> and weekly <font color="red">creatinine_1</font> <font color="red">clearance_1</font> <font color="red">._1</font> Two - way analysis of variance for repeated measurements was used for statistical analysis . <font color="red">Systolic_1</font> <font color="red">and_1</font> <font color="red">diastolic_1</font> <font color="red">BP_1</font> were both reduced in patients treated with ARB . The <font color="red">LVMi_1</font> was significantly reduced in patients treated with ARB ( to 121 + /- 4 from 145 + /- 5 ) but not in those receiving placebo ( to 137 + /- 3 from 152 + /- 3 , p < 0.05 ) . The decrease in <font color="red">LVMi_1</font> was associated with a reduction in <font color="red">PWV_1</font> and <font color="red">AI_1</font> <font color="red">._1</font> In CAPD patients with LVH , ARB reduced <font color="red">LVMi_1</font> in association with alterations in arterial hemodynamics .